It looks like you are using an older version of Internet Explorer which is not supported. We advise that you update your browser to the latest version of Microsoft Edge, or
consider using other browsers such as Chrome, Firefox or Safari.
Everyone is different, and like any other decision you make when it comes to your health, we know it may be overwhelming to get started. Choose a trial below or use the search to find what you're looking for.
A Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase III Multicenter Study of Intravenous Secukinumab to Compare Efficacy at 16 Weeks With Placebo and to Assess Safety and Tolerability up to 52 Weeks in Subjects With Active Ankylosing Spondylitis or Non-radiographic Axial SpondyloArthritis
ClinicalTrials.gov ID: NCT04156620 | Gender: All | Age(s): 18 Years and older (Adult, Older Adult) | Drug: Secukinumab & Placebo
A Randomized, Double-blind, Parallel-group, Multicenter Study of Secukinumab to Compare 300 mg and 150 mg at Week 52 in Patients With Ankylosing Spondylitis Who Are Randomized to Dose Escalation After Not Achieving Inactive Disease During an Initial 16 Weeks of Open-label Treatment With Secukinumab 150 mg (ASLeap)
ClinicalTrials.gov ID: NCT03350815 | Gender: All | Age(s): 18 Years and older (Adult, Older Adult) | Drug: 150 mg open-label secukinumab, 150 mg double-blinded secukinumab & 3300 mg double-blinded secukinumab